Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
JD Supra4d
Ozempic Lawsuit Update: New Study Links Semaglutides to Increased Risk of Vision Loss
More plaintiffs are continuing to join the diabetes drug Ozempic lawsuits against Novo Nordisk; and, until a couple of weeks ...
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...
GLP-1 pills are coming, and they could revolutionize weight-loss treatment
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...
pharmaphorum3d
Noom offers cut-price compounded GLP-1 drug for obesity
Noom is best known for its eponymous app that helps people become healthier and lose weight by making changes to their diet ...
Why millions are trying FDA-authorized alternatives to weight loss drugs
Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself “at my ideal ...
CNN4d
GLP-1 pills are coming, and they could revolutionize weight-loss treatment
But Novo Nordisk declined to say whether it’s filed ... and sales of an oral form of semaglutide for type 2 diabetes, approved as Rybelsus, have been dwarfed by those of injectable Ozempic.